Status:
COMPLETED
The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease
Lead Sponsor:
Huashan Hospital
Collaborating Sponsors:
Boehringer Ingelheim
Conditions:
Idiopathic Parkinson's Disease
Eligibility:
All Genders
30-75 years
Phase:
NA
Brief Summary
Levodopa and non-ergot dopaminergic agonists such as pramipexole are both recommended as the first-line symptomatic treatment for early untreated Parkinson's disease (PD), previous clinical trial indi...
Detailed Description
CALM-PD study found that Pramipexole can reduce the occurrence of motor complication compared with Levodopa used as initiative treatment, but it still remains debatable that initiation of which medica...
Eligibility Criteria
Inclusion
- idiopathic Parkinson's disease meeting United Kingdom (UK) brain bank criteria
- De Novo
- Hoehn\&Yahr staging (H\&Y) I-II
Exclusion
- Atypical Parkinsonism
- Pregnant or breast-feeding women
- those with abnormal Liver/kidney function
- those participating other clinical trials within 30 days before being enrolled for this trial.
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01470859
Start Date
December 1 2011
End Date
August 1 2014
Last Update
October 21 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China, 200040